SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Mainardi, Sara

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. [electronic resource] - Nature medicine 07 2018 - 961-967 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1546-170X

10.1038/s41591-018-0023-9 doi


Animals
Carcinoma, Non-Small-Cell Lung--genetics
Cell Line, Tumor
Cell Proliferation--drug effects
Cellular Senescence--drug effects
Guanosine Triphosphate--metabolism
Humans
Lung Neoplasms--genetics
Mice
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Mutation--genetics
Protein Kinase Inhibitors--pharmacology
Protein Tyrosine Phosphatase, Non-Receptor Type 11--metabolism
Proto-Oncogene Proteins p21(ras)--genetics
Xenograft Model Antitumor Assays